IRVINE, Calif., Nov. 17, 2005 (PRIMEZONE) -- "The anticipated abundance of aging patients in the coming years is a key factor in the advent of many new technologies within the biotechnology umbrella," stated SmallCap Sentinel analyst, D.R. Clark. "We're seeing a concerted effort to develop the 'better mousetrap' as companies endeavor to get through development, FDA approvals and eventual product introduction at a commercial level."
"Unique and improved applications of the transdermal patch, literally and figuratively speaking, are a perfect example," Clark added. "Dermisonic's recent announcement that the company has received approval from the Chesapeake Research Review Investigative Review Board to enter into the next stage of human pilot trials of its proprietary U-Strip(tm) Insulin Patch drug-delivery system in patients with Type-2 diabetes affirms the company's continued success in incubating their core technology."
Dermisonics, Inc. (OTCBB:DMSI) is a medical device company formed to exploit the vast opportunities for non-invasive, reliable and easy to use delivery of large molecule drugs through its unique, proprietary transdermal patch called the U-Strip.
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com
The report will address issues regarding biotechnology and pharmaceutical companies such as Medimmune Inc. (Nasdaq:MEDI), Genentech Inc. (NYSE:DNA), Novartis AG (NYSE:NVS) and Dermisonics among others.
Interested parties may view information about DMSI free of charge via this direct link: http://www.trilogy-capital.com/dmsi_summary.aspx
Forward-Looking Statements
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by Dermisonics Inc. for preparation and distribution of this report and other advertising services. This release has been approved by the company or its representatives. Additionally, MP and/or its affiliates, associates and employees from time to time may have either a long or short position in any securities mentioned. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.